THE USE OF THE AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN SUBJECTS ABOVE 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)

THE USE OF THE AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN SUBJECTS ABOVE 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)

The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ILIAS BULATOVICH ESMAGAMBETOV, ELIZAVETA ALEXANDROVNA TOKARSKAYA, BORIS SAVELIEVICH NARODITSKY, SVETLANA YAKOVLEVNA LOGINOVA, FATIMA MAGOMETOVNA IZHAEVA, VLADIMIR ALEKSANDROVICH CHERNETSOV, DENIS YURYEVICH LOGUNOV, NATALIA MIKHAILOVNA TUKHVATULINA, ALINA SHAHMIROVNA DZHARULLAEVA, NADEZHDA LEONIDOVNA LUBENETS, ALINA SERGEEVNA EROKHOVA, DMITRII VIKTOROVICH SHCHEBLIAKOV, DARIA MIKHAILOVNA GROUSOVA, VLADIMIR FEDOROVICH BABIRA, ALEKSANDR SERGEEVICH SEMIKHIN, DMITRII ANATOLIEVICH KUTAEV, ALEKSANDR LEONIDOVICH GINTSBURG, DMITRII NIKOLAEVICH SHCHERBININ, AMIR ILDAROVICH TUKHVATULIN, BOTIKOV, ANDREI GENNADEVICH, OLGA VADIMOVNA ZUBKOVA, INNA VADIMOVNA DOLZHIKOVA, NATALIA ANATOLEVNA NIKITENKO, EVGENII VLADIMIROVICH KRIUKOV, TATIANA ANDREEVNA OZHAROVSKAIA, OLGA POPOVA
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention relates to the field of biotechnology, immunology and virology. The use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and/or containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. In addition the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 26 with E1 and E3 sites deleted from the genome, and the site ORF6-Ad26 is substituted for ORF6-Ad5 with integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, or containing only component 2 for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subjects above 60 years of age and/or having chronic diseases. Furthermore, the use of the agent is disclosed, said agent containing a component 1, which is an agent in the form of expression vector based on genome of recombinant strain of simian adenovirus serotype 25 with E1 and E3 sites deleted from the genome with integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, SEQ ID NO:3, and also containing a component 2, which is an agent in the form of expression vector based on genome of recombinant strain of human adenovirus serotype 5 with E1 and E3 sites deleted from the genome with the integrated expression cassette selected from SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2 in subje